Summary

The 7 major bacterial vaginosis markets reached a value of US$ 762.8 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,405.4 Million by 2034, exhibiting a growth rate (CAGR) of 5.71% during 2024-2034.

The bacterial vaginosis market has been comprehensively analyzed in IMARC's new report titled "Bacterial Vaginosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bacterial vaginosis is a form of vaginal infection caused by an overgrowth of the normally occurring bacteria in the vagina. The disease is triggered by a reduction in the amount of typical hydrogen peroxide-producing lactobacilli (good bacteria), along with an increase in anaerobic (bad) bacteria. This results in an imbalance of bacterial flora within the vagina, which can even raise the likelihood of sexually transmitted infections among patients. Many women with bacterial vaginosis have no signs or symptoms. In other cases, the common indications of the ailment include thin, gray, green, or white vaginal discharge; a foul-smelling, fishy vaginal odor; itching; irritation; a burning sensation during urination, etc. The diagnosis of this illness typically requires a combination of the underlying symptoms, medical history, and a physical test. The healthcare professional may perform a pelvic exam to determine the characteristics of the vaginal discharge and to rule out other possible causes. Some of the frequently used diagnostic workups include gram staining of vaginal secretions, presence of clue cells on wet mount, whiff test, etc.

The increasing utilization of vaginal douches or feminine hygiene products, which can disrupt the normal bacterial balance in the vagina, is primarily driving the bacterial vaginosis market. In addition to this, the rising incidence of several associated risk factors, such as multiple sexual partners, unprotected sex, cigarette smoking, use of an intrauterine device, etc., is also bolstering the market growth. Furthermore, the widespread adoption of nitroimidazole antimicrobials and lincosamide antibiotics to destroy or stop the proliferation of bacteria causing the condition is acting as another significant growth-inducing factor. Apart from this, the inflating application of lactobacillus colonization therapy, which aims to boost the number of good bacteria in the vagina and re-establish a stabilized vaginal environment in patients, is further creating a positive outlook for the market. Additionally, the ongoing development of intravaginal anti-infective boric acid enhanced with ethylenediaminetetraacetic acid (EDTA) for treating the ailment since they can improve activity against harmful bacteria while protecting the beneficial lactobacilli is expected to drive the bacterial vaginosis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the bacterial vaginosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bacterial vaginosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bacterial vaginosis market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bacterial vaginosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bacterial vaginosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bacterial vaginosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the bacterial vaginosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the bacterial vaginosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the bacterial vaginosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of bacterial vaginosis across the seven major markets?
What is the number of prevalent cases (2018-2034) of bacterial vaginosis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of bacterial vaginosis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with bacterial vaginosis across the seven major markets?
What is the size of the bacterial vaginosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of bacterial vaginosis?
What will be the growth rate of patients across the seven major markets?

Bacterial Vaginosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for bacterial vaginosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bacterial vaginosis market?
What are the key regulatory events related to the bacterial vaginosis market?
What is the structure of clinical trial landscape by status related to the bacterial vaginosis market?
What is the structure of clinical trial landscape by phase related to the bacterial vaginosis market?
What is the structure of clinical trial landscape by route of administration related to the bacterial vaginosis market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Bacterial Vaginosis - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Bacterial Vaginosis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Bacterial Vaginosis - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Diagnosed Cases (​2018-2034​)
7.2.6 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Diagnosed Cases (​2018-2034​)
7.3.6 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Diagnosed Cases (​2018-2034​)
7.4.6 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Diagnosed Cases (​2018-2034​)
7.5.6 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Diagnosed Cases (​2018-2034​)
7.6.6 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Diagnosed Cases (​2018-2034​)
7.7.6 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Diagnosed Cases (​2018-2034​)
7.8.6 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Diagnosed Cases (​2018-2034​)
7.9.6 Patient Pool/Treated Cases (​2018-2034​)

8 Bacterial Vaginosis - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Bacterial Vaginosis - Unmet Needs

10 Bacterial Vaginosis - Key Endpoints of Treatment

11 Bacterial Vaginosis - Marketed Products
11.1 List of Bacterial Vaginosis Marketed Drugs Across the Top 7 Markets
11.1.1 Nuvessa (Metronidazole vaginal gel) - AbbVie
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Cleocin (Clindamycin) - Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Solosec (Secnidazole) - Lupin
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Xaciato (Clindamycin) - Dare Bioscience
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Tindamax (Tinidazole) – Mission Pharmacal
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Bacterial Vaginosis - Pipeline Drugs
12.1 List of Bacterial Vaginosis Pipeline Drugs Across the Top 7 Markets
12.1.1 Lactin V - Osel Inc
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 TOL 463 - Toltec Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Bacterial Vaginosis - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Bacterial Vaginosis – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Bacterial Vaginosis - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bacterial Vaginosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Bacterial Vaginosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Bacterial Vaginosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Bacterial Vaginosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Bacterial Vaginosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bacterial Vaginosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Bacterial Vaginosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Bacterial Vaginosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bacterial Vaginosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Bacterial Vaginosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Bacterial Vaginosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bacterial Vaginosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Bacterial Vaginosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Bacterial Vaginosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bacterial Vaginosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Bacterial Vaginosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Bacterial Vaginosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bacterial Vaginosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Bacterial Vaginosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Bacterial Vaginosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bacterial Vaginosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Bacterial Vaginosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Bacterial Vaginosis - Access and Reimbursement Overview

16 Bacterial Vaginosis - Recent Events and Inputs From Key Opinion Leaders

17 Bacterial Vaginosis Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Bacterial Vaginosis Market – Strategic Recommendations

19 Appendix